pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of included studies

Study Study design Apixaban N Warfarin N CKD Stage Apixaban vs Warfarin N(%) Body weight (kg)/BMI, mean±SD (range) Age (years) mean±SD (range) Apixaban dose



Apixaban Warfarin Apixaban Warfarin Apixaban dose N (%)
Stanifer, J.W 2020 26) RCT 135 132 CrCl 25-30 mL/min BWt: 58(49-65) BWt: 57±8 81(76-85) 81±4 5 mg bid
48(35.6)
87(64.4)
Herndon 2020 21) cohort 54 57 CKD 4: 31(57) vs 26(46)
CKD 5: 23(43) vs 31(54)
BWt: 92±19
BMI: 29±6
NA 72±8 71±8 5 mg bid
2.5 mg bid
25(46.3)
29(53.7)
Reed, D. 2018 22) cohort 74 50 ESRD or ESRD in HD/PD BWt: 86.1±27.0
BMI: 27.9±6.5
BWt: 79.0±20.5
BMI: 29.2±10.1 59.5±14.7 62.0±14.4 5 mg bid
2.5 mg bid
59(79.7)
15(20.3)
Schafer, J.H 2018 24) cohort 302 302 CKD 4:197(65.2) vs 182(60.3)
CKD 5:105(34.8) vs 120(39.7)
BWt: 81.2(68-95.6) BWt: 84.8(68.7-99.8) 73.5±12.1 70.6±13.8 5 mg bid
2.5 mg bid
129(43)
173(57)
Siontis, K. C. 2018 25) cohort 2351 7053 ESRD in HD/PD NA NA 68.87±11.5 68.15±11.9 mg bid
2.5 mg bid
1034(44)
1317(56)
Sarratt, S.C. 2017. 23) cohort 40 120 CKD 5 (CrCl <15 mL/min) BWt: 78.3(59-97) BWt: 83.0±25 70.9(60-81) 66.5±13.5 5 mg bid
2.5 mg bid
17(42.5)
23(57.5)
Stanton, B.E 2017. 27) cohort 73 73 CrCl <25 mL/min or
SCr >2.5 mg/dL (included 3 patients
with CrCl 26-36 mL/dL)
BWt: 82±24.5 BWt: 81.5±23.7 79±11.8 79±13.5 10 mg bid
5 mg bid
2.5 mg bid
1(1.4)
45(61.6)
27(37)

Bid, Twice daily; BWt, Body weight; BMI, Body mass index; CKD, Chronic kidney disease; CrCl, Creatinine clearance; ESRD, End-stage renal disease; HD, Hemodialysis; N, number of patients; NA, Not available; PD, Peritoneal dialysis; RCT, Randomized controlled trials; SD, Standard deviation

Korean J Clin Pharm 2021;31:87-95 https://doi.org/10.24304/kjcp.2021.31.2.87
© 2021 Korean J Clin Pharm